Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company that specializes in developing and commercializing innovative biopharmaceuticals for serious and life-threatening rare genetic diseases. They generate revenue primarily through the sale of their approved therapies and by licensing their technologies. Founded in 1997, BioMarin has a notable history of pioneering treatments, including the first approved enzyme replacement therapy for MPS I, a rare lysosomal storage disorder. The company is headquartered in San Rafael, California, and continues to focus on advancing its robust pipeline of clinical and preclinical candidates.

Recent Posts by Biomarin Pharmaceutical

1-20 of 332